Is Enjamb profitable in 2026?

No independently verified revenue exists for Enjamb as of 2026-07-27. The company is pre-seed, roughly two months past its May 28, 2026 YC public launch, with total disclosed capital raised of just $650K from Y Combinator and Founders Inc.

Could AI replace Enjamb itself?

Enjamb's own product is agentic AI drafting regulatory documents, so it is highly exposed: it benchmarks itself against GPT-5.5 in its own marketing (2026-05-28 YC launch), and a frontier lab shipping a comparable pharma-integrated agent could commoditize it quickly.

Who is Enjamb's biggest competitor or threat?

Veeva Vault, the validated regulatory system of record Enjamb builds on top of, is the main structural threat. Veeva began shipping its own AI agents into Vault on 2025-12-03, giving it a direct path to add the same document-drafting features Enjamb offers.

Who owns Enjamb / who funds it?

Enjamb Labs is privately held and venture-backed at pre-seed stage, with $650K raised from Y Combinator and Founders Inc (f.inc), per CB Insights as of 2026-07-27. No valuation has been publicly disclosed.

Does Enjamb have real, confirmed pharma customers?

Enjamb claims 500+ pharma employees used it within 3 weeks of its May 28, 2026 launch, including staff at J&J, AbbVie, BMS, Merck and Sanofi, but as of 2026-07-27 none of these companies has independently confirmed the claim via press release.

Has Enjamb raised a seed round?

As of 2026-07-27, Enjamb Labs' disclosed total funding remains $650K at pre-seed from Y Combinator and Founders Inc; no seed or Series A round beyond this has been publicly announced.

YC Spring 2026 · United States

Enjamb

enjamb.ai ↗

Agentic AI workspace helping drug teams draft trials, stats, and FDA filings.

Losing its protection

Assessed 27 July 2026 · Evidence as of 27 July 2026

The structural protection is eroding.

On the recordSince 27 July 2026 · Checkable from Q4 2026 · Every call on the record Checkpoint: Veeva's next Vault R&D platform update cycle, where agentic drafting features could ship

The call

Enjamb is a two-person team layering AI drafting on top of tools pharma already owns, with traction claims no named customer has confirmed.

Enjamb is software that sits on top of systems like Veeva and Medidata to automate tasks for drug companies and research labs. The challenge: Enjamb does not replace these systems, so the companies that own them (like Veeva) could build the same automation themselves without needing Enjamb, and they have more trust with customers already. The one thing that could change this is if Enjamb builds deep regulatory approval and trust with the FDA that big vendors cannot easily replicate, or if real customers publicly say it saved them time and money.

Why

AI pressure: OpenAI, Anthropic, or Google building a vertical pharma-agent product. A frontier lab could bundle regulatory drafting into its general agent, undercutting Enjamb's whole pitch. Could AI do the core job? Yes, likely.

Bigger players: Veeva Vault (with Medidata, SAS, Benchling). Enjamb runs on top of these systems; any of them shipping its own compliant drafting agent removes Enjamb's reason to exist. Could a giant copy it? Yes, easily.

What protects it. Being first to stitch these tools into one workflow, though no validated FDA-grade trust or named pharma filing exists yet.

What would change this call

A named pharma company (e.g. J&J, Merck) issues a press release or case study confirming Enjamb use. Would convert vendor-claimed traction into verified customer adoption.
Veeva, Medidata, or SAS ships a compliant AI document-drafting feature within 12 months. Would show incumbents closing the gap Enjamb depends on staying open.
Enjamb announces a seed or Series A round beyond the $650K pre-seed. Would signal investor confidence that the workflow layer can be defended.

Key numbers

$650K raised total, from YC and Founders Inc. (2026-07-27)
2-person founding team, no regulatory hires yet (2026-07-27)
Claims 500+ pharma users in 3 weeks, unconfirmed (2026-05-28)

Named risks

Two-person founding team with no disclosed hiring, single points of failure. Severity: high
Core traction claims (500+ users, named pharma logos) are vendor-authored and unconfirmed by any named customer. Severity: high
Incumbent Veeva Vault already shipping AI agents that could replicate Enjamb's document-drafting layer. Severity: high
No disclosed revenue or pricing model at pre-seed stage two months post-launch. Severity: medium
Regulatory liability exposure if AI-drafted FDA submission content contains errors. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Veeva Vault	gaining on	Shipped own AI Agents into Vault on 2025-12-03, ahead of Enjamb's May 2026 launch
Nabla Bio	contesting	Reports strategic deals with AstraZeneca, BMS, and a $1B+ Takeda milestone deal by mid-2026
CROs (IQVIA, ICON, Parexel, Syneos)	contesting	Face billable-hours business-model conflict from AI automation of medical writing per 2026-04-01 analysis
OpenAI/Anthropic/Google (frontier labs)	contesting	No dated pharma-workflow agent launch found as of 2026-07-27, but Enjamb benchmarks vs GPT-5.5

Questions people ask

Is Enjamb profitable in 2026?: No independently verified revenue exists for Enjamb as of 2026-07-27. The company is pre-seed, roughly two months past its May 28, 2026 YC public launch, with total disclosed capital raised of just $650K from Y Combinator and Founders Inc.
Could AI replace Enjamb itself?: Enjamb's own product is agentic AI drafting regulatory documents, so it is highly exposed: it benchmarks itself against GPT-5.5 in its own marketing (2026-05-28 YC launch), and a frontier lab shipping a comparable pharma-integrated agent could commoditize it quickly.
Who is Enjamb's biggest competitor or threat?: Veeva Vault, the validated regulatory system of record Enjamb builds on top of, is the main structural threat. Veeva began shipping its own AI agents into Vault on 2025-12-03, giving it a direct path to add the same document-drafting features Enjamb offers.
Who owns Enjamb / who funds it?: Enjamb Labs is privately held and venture-backed at pre-seed stage, with $650K raised from Y Combinator and Founders Inc (f.inc), per CB Insights as of 2026-07-27. No valuation has been publicly disclosed.
Does Enjamb have real, confirmed pharma customers?: Enjamb claims 500+ pharma employees used it within 3 weeks of its May 28, 2026 launch, including staff at J&J, AbbVie, BMS, Merck and Sanofi, but as of 2026-07-27 none of these companies has independently confirmed the claim via press release.
Has Enjamb raised a seed round?: As of 2026-07-27, Enjamb Labs' disclosed total funding remains $650K at pre-seed from Y Combinator and Founders Inc; no seed or Series A round beyond this has been publicly announced.

Timeline

2026-07-27Brief date: still 2-person team, no independently verified revenue, no lawsuits found
2026-07-21Enjamb.org claims 100+ integrations (Veeva, Medidata, SAS, Benchling) and 50+ scientific models
2026-05-28YC Spring 2026 public launch as Enjamb Labs, 'Claude Code for Drug Discovery'
2026-05-28Company claims 500+ pharma users in 3 weeks at J&J, AbbVie, BMS, Merck, Sanofi
2026-01-02Unrelated YC company AnswerThis claims $1M ARR; not Enjamb, clarified to avoid conflation
2025-12-03Veeva ships its own AI Agents into Vault, encroaching on Enjamb's layer
2025Enjamb founded, initially as broad agentic research workspace for scientists

Revision history

27 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Trellis Surtr Defense Systems HeyClicky